Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

360 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The current and future burden of hepatitis B in Switzerland: a modelling study.
Negro F, Müllhaupt B, Semela D, Blach S, Bruggmann P, De Gottardi A, Dufour JF, Fraga M, Galante A, Razavi H, Vieira Barbosa J, Razavi-Shearer D. Negro F, et al. Among authors: dufour jf. Swiss Med Wkly. 2023 Jun 5;153:40086. doi: 10.57187/smw.2023.40086. Swiss Med Wkly. 2023. PMID: 37410921 Free article.
Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study.
Lee J, Westphal M, Vali Y, Boursier J, Petta S, Ostroff R, Alexander L, Chen Y, Fournier C, Geier A, Francque S, Wonders K, Tiniakos D, Bedossa P, Allison M, Papatheodoridis G, Cortez-Pinto H, Pais R, Dufour JF, Leeming DJ, Harrison S, Cobbold J, Holleboom AG, Yki-Järvinen H, Crespo J, Ekstedt M, Aithal GP, Bugianesi E, Romero-Gomez M, Torstenson R, Karsdal M, Yunis C, Schattenberg JM, Schuppan D, Ratziu V, Brass C, Duffin K, Zwinderman K, Pavlides M, Anstee QM, Bossuyt PM; LITMUS investigators. Lee J, et al. Among authors: dufour jf. Hepatology. 2023 Jul 1;78(1):258-271. doi: 10.1097/HEP.0000000000000364. Epub 2023 Mar 31. Hepatology. 2023. PMID: 36994719
Normalization of lipid oxidation defects arising from hypoxia early posthepatectomy prevents liver failure in mouse.
Birrer DL, Kachaylo E, Breuer E, Linecker M, Kron P, Ungethüm U, Hagedorn C, Steiner R, Kälin C, Borrego LB, Dufour JF, Foti M, Hornemann T, Clavien PA, Humar B. Birrer DL, et al. Among authors: dufour jf. Am J Transplant. 2023 Feb;23(2):190-201. doi: 10.1016/j.ajt.2022.10.003. Epub 2023 Jan 12. Am J Transplant. 2023. PMID: 36804129 Free article.
Non-invasive assessment of MASH resolution.
Dufour JF, Wong VW. Dufour JF, et al. Gut. 2024 Mar 13:gutjnl-2024-332060. doi: 10.1136/gutjnl-2024-332060. Online ahead of print. Gut. 2024. PMID: 38479806 No abstract available.
Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information.
McTeer M, Applegate D, Mesenbrink P, Ratziu V, Schattenberg JM, Bugianesi E, Geier A, Romero Gomez M, Dufour JF, Ekstedt M, Francque S, Yki-Jarvinen H, Allison M, Valenti L, Miele L, Pavlides M, Cobbold J, Papatheodoridis G, Holleboom AG, Tiniakos D, Brass C, Anstee QM, Missier P; LITMUS Consortium investigators. McTeer M, et al. Among authors: dufour jf. PLoS One. 2024 Feb 29;19(2):e0299487. doi: 10.1371/journal.pone.0299487. eCollection 2024. PLoS One. 2024. PMID: 38421999 Free PMC article.
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Pericàs JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V; MAESTRO-NASH Investigators. Harrison SA, et al. N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000. N Engl J Med. 2024. PMID: 38324483 Clinical Trial.
A pivotal year for NAFLD and NASH therapeutics.
Dufour JF. Dufour JF. Nat Rev Endocrinol. 2024 Feb;20(2):75-76. doi: 10.1038/s41574-023-00939-9. Nat Rev Endocrinol. 2024. PMID: 38097670 No abstract available.
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
Zeng Q, Klein C, Caruso S, Maille P, Allende DS, Mínguez B, Iavarone M, Ningarhari M, Casadei-Gardini A, Pedica F, Rimini M, Perbellini R, Boulagnon-Rombi C, Heurgué A, Maggioni M, Rela M, Vij M, Baulande S, Legoix P, Lameiras S; HCC-AI study group; Bruges L, Gnemmi V, Nault JC, Campani C, Rhee H, Park YN, Iñarrairaegui M, Garcia-Porrero G, Argemi J, Sangro B, D'Alessio A, Scheiner B, Pinato DJ, Pinter M, Paradis V, Beaufrère A, Peter S, Rimassa L, Di Tommaso L, Vogel A, Michalak S, Boursier J, Loménie N, Ziol M, Calderaro J. Zeng Q, et al. Lancet Oncol. 2023 Dec;24(12):1411-1422. doi: 10.1016/S1470-2045(23)00468-0. Epub 2023 Nov 8. Lancet Oncol. 2023. PMID: 37951222
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis.
Sanyal AJ, Ratziu V, Loomba R, Anstee QM, Kowdley KV, Rinella ME, Sheikh MY, Trotter JF, Knapple W, Lawitz EJ, Abdelmalek MF, Newsome PN, Boursier J, Mathurin P, Dufour JF, Berrey MM, Shiff SJ, Sawhney S, Capozza T, Leyva R, Harrison SA, Younossi ZM. Sanyal AJ, et al. Among authors: dufour jf. J Hepatol. 2023 Nov;79(5):1110-1120. doi: 10.1016/j.jhep.2023.07.014. Epub 2023 Jul 28. J Hepatol. 2023. PMID: 37517454 Free article.
360 results